In general, biosimilars are generic products of biopharmaceuticals. Different from generics, they are “similar” and therefore require approval procedures similar to new branded drugs. Although there are about 25 approved biosimilars in Europe, they did not receive the same treatment in the United States. Despite 11 drugs are approved in the United States, only about 3 kinds can be utilized in patients for branded pharmaceutical companies are using commercial…
Industry Report
Market and R&D Analysis of Recombinant Protein Drugs
According to the report of Grand View Research, the demand for recombinant technology, pharmaceutical biotechnology, and DNA sequencing technology is increasing based on disease diagnosis and treatment requirement, and the global biotechnology market is expected to grow at a compound annual growth rate of 12.3%. By 2020, the market size will be $606.8 billion. Recombinant protein, a genetic engineering and cell engineering technology, produced from the creature body, has become…